Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. Rosen Law Firm is investigating potential securities fraud claims and preparing a class action lawsuit on behalf of affected shareholders.